Prescription drug · ANDA
Etomidate NDC 51662-1485
Etomidate 2 mg/mL · Injection · Intravenous · HF Acquisition Co LLC, DBA HealthFirst
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51662-1485-1 | 51662148501 | 10 mL in 1 VIAL, SINGLE-DOSE (51662-1485-1)Marketed from Jan 11, 2020 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Etomidate
- Generic name (nonproprietary)
- etomidate
- Active ingredients
- Etomidate — 2 mg/mL
- Dosage form
- Injection
- Route
- Intravenous
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202354
- Marketing start
- Listing expires
- Other FDA classes
- General Anesthesia (Physiologic effect)
- Identifiers
- Product ID 51662-1485_2b39a9d5-ca76-b107-e063-6394a90ae8bbSPL ID 2b39a9d5-ca76-b107-e063-6394a90ae8bbSPL set ID 9bdee875-4b48-c592-e053-2995a90a6485RxCUI 1654006UNII Z22628B598
- Pharmacologic class
- General Anesthetic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N451662148501followed by a unit qualifier and the quantityPackage 51662-1485-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS & USAGE Etomidate Injection, USP is indicated by intravenous injection for induction of general anesthesia. When considering use of etomidate, the usefulness of its hemodynamic properties (see CLINICAL PHARMACOLOGY ) should be weighed against the high frequency of transient skeletal muscle movements (see ADVERSE REACTIONS ). Intravenous etomidate is also indicated for supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 202354
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9507 |
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9310 |
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9311 |
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Civica, Inc. | 72572-160 |
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Civica, Inc. | 72572-161 |
| Etomidate | Etomidate 2 mg/mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9506 |